Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
What leeches reveal about movement
Lidia Szczupak turned to the animals to explore how the nervous system coordinates movement.
What leeches reveal about movement
Lidia Szczupak turned to the animals to explore how the nervous system coordinates movement.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Scientific talent is global. Access to the world’s scientific stage is not.
Neuroscience in Chile, and across Latin America, does not lack talent or ideas, but the systems that make science visible—prestigious journals, conferences and networks—increasingly price its researchers out.
Scientific talent is global. Access to the world’s scientific stage is not.
Neuroscience in Chile, and across Latin America, does not lack talent or ideas, but the systems that make science visible—prestigious journals, conferences and networks—increasingly price its researchers out.